Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 6/20 | 0.35 |
| ▸ | MMP3 | P08254 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 4/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16882307 | 0.86 | DPP7 (0.50) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL8403553 | 0.83 | DPP7 (0.48) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20705075 | 0.81 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20705091 | 0.81 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL8163475 | 0.81 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL15959310 | 0.81 | DPP7 (0.50) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20705089 | 0.81 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20705077 | 0.81 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL13555514 | 0.81 | DPP7 (0.46) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20414881 | 0.81 | DPP7 (0.54) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | DPP7 1481/4885GNAI3 2268/4885GNAO1 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.